KDM1A and breast carcinoma: Inhibiting LSD1 causes a loss in the mesenchymal signature in breast cancer cells, as well as in patient-derived circulating tumor cells, providing evidence for LSD1 as a potential therapeutic target for reversing the EMT process, particularly in CSCs.